ImageneBio (IMA) Financials

ImageneBio logo
$3.24 +0.04 (+1.25%)
As of 11:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for ImageneBio

Annual Income Statements for ImageneBio

This table shows ImageneBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-44 -34 -69 -68 -48 -52
Consolidated Net Income / (Loss)
-44 -34 -69 -68 -37 -45
Net Income / (Loss) Continuing Operations
-44 -34 -69 -68 -37 -45
Total Pre-Tax Income
-44 -34 -69 -68 -37 -46
Total Operating Income
-45 -34 -71 -75 -37 -48
Total Gross Profit
9.19 31 16 9.16 3.50 0.80
Total Revenue
9.19 31 16 9.16 3.50 0.80
Operating Revenue
9.19 31 16 9.16 3.50 0.80
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
54 65 87 85 41 49
Selling, General & Admin Expense
8.87 18 22 25 8.39 21
Research & Development Expense
45 47 64 60 32 29
Total Other Income / (Expense), net
0.26 0.05 2.14 7.09 0.45 2.75
Interest & Investment Income
- 0.02 2.15 7.11 0.37 2.04
Other Income / (Expense), net
0.26 0.02 -0.01 -0.02 0.07 0.72
Income Tax Expense
- - 0.00 -0.16 0.01 -0.35
Preferred Stock Dividends Declared
- - - - 12 7.05
Basic Earnings per Share
($16.00) ($1.22) ($1.90) ($1.63) ($66.30) ($9.64)
Weighted Average Basic Shares Outstanding
2.77M 27.98M 36.19M 41.74M 3.38M 4.87M
Diluted Earnings per Share
($16.00) ($1.22) ($1.90) ($1.63) ($66.30) ($9.64)
Weighted Average Diluted Shares Outstanding
2.77M 27.98M 36.19M 41.74M 2.19M 0.00

Quarterly Income Statements for ImageneBio

This table shows ImageneBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-16 -14 -6.18 -9.12 -9.13 -11 -26 -15 -11 -10 -16
Consolidated Net Income / (Loss)
-16 -14 -3.18 -9.12 -6.08 -7.59 -25 -9.18 -11 -10 -16
Net Income / (Loss) Continuing Operations
-16 -14 -3.18 -9.12 -6.08 -7.59 -25 -9.18 -11 -10 -16
Total Pre-Tax Income
-16 -14 -3.18 -9.07 -6.08 -7.59 -25 -9.50 -11 -10 -16
Total Operating Income
-18 -16 -2.04 -13 -6.00 -7.36 -26 -2.31 -12 -12 -17
Total Gross Profit
0.00 0.00 3.50 - 0.80 0.00 0.00 0.80 0.00 0.00 0.00
Total Revenue
0.00 0.00 3.50 - 0.80 0.00 0.00 0.80 0.00 0.00 0.00
Operating Revenue
0.00 0.00 3.50 - 0.80 0.00 0.00 0.80 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
18 16 5.54 13 6.80 7.36 26 3.11 12 12 17
Selling, General & Admin Expense
6.00 5.31 1.65 7.60 2.76 1.71 11 -0.37 6.12 5.12 6.04
Research & Development Expense
9.65 9.83 3.89 4.58 4.04 5.65 15 5.23 5.96 6.67 11
Total Other Income / (Expense), net
2.11 2.16 -1.15 3.45 -0.08 -0.23 1.34 -7.19 1.47 1.62 1.71
Interest & Investment Income
2.11 1.92 0.05 1.57 -0.08 -0.24 1.06 -0.58 1.13 1.25 1.19
Other Income / (Expense), net
-0.01 0.24 -1.19 1.88 -0.01 0.01 0.28 -6.61 0.34 0.37 0.52
Income Tax Expense
0.03 0.06 0.00 0.05 0.00 0.00 -0.07 -0.32 0.01 0.02 0.02
Preferred Stock Dividends Declared
- - 3.00 - 3.05 3.15 0.85 - 0.00 0.00 0.00
Basic Earnings per Share
($0.33) ($0.28) ($2.58) ($0.20) ($3.80) ($4.46) ($2.91) ($3.16) ($0.95) ($0.63) ($0.91)
Weighted Average Basic Shares Outstanding
48.26M 48.26M 1.40M 48.26M 3.81M 3.82M 8.80M 4.87M 22.42M 0.00 17.12M
Diluted Earnings per Share
($0.33) ($0.28) ($2.58) ($0.20) ($3.80) ($4.46) ($2.91) ($3.16) ($0.95) ($0.63) ($0.91)
Weighted Average Diluted Shares Outstanding
48.26M 48.26M 0.00 48.26M 4.81M 4.81M 8.80M 0.00 22.42M 16.16M 17.12M
Weighted Average Basic & Diluted Shares Outstanding
48.26M 48.26M 48.26M 48.26M 48.26M 48.26M 11.18M 0.00 11.28M 11.35M 12.46M

Annual Cash Flow Statements for ImageneBio

This table details how cash moves in and out of ImageneBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
81 70 -172 60 -3.20 82
Net Cash From Operating Activities
-38 -60 -74 -80 -21 -48
Net Cash From Continuing Operating Activities
-38 -60 -74 -80 -21 -48
Net Income / (Loss) Continuing Operations
-44 -34 -69 -68 -37 -45
Consolidated Net Income / (Loss)
-44 -34 -69 -68 -37 -45
Depreciation Expense
0.30 0.54 0.75 1.02 1.14 0.40
Amortization Expense
- 0.00 0.05 -2.02 0.39 0.56
Non-Cash Adjustments To Reconcile Net Income
14 6.35 8.99 11 15 16
Changes in Operating Assets and Liabilities, net
-7.77 -33 -15 -22 -1.52 -19
Net Cash From Investing Activities
2.92 -1.76 -99 64 11 -5.81
Net Cash From Continuing Investing Activities
2.92 -1.76 -99 64 11 -5.81
Acquisitions
- - - - 0.00 -5.22
Purchase of Investments
- 0.00 -216 -90 0.00 -10
Sale of Property, Plant & Equipment
- - - 0.00 0.97 0.00
Sale and/or Maturity of Investments
- 0.00 118 155 10 9.80
Net Cash From Financing Activities
116 132 1.10 76 6.91 135
Net Cash From Continuing Financing Activities
116 132 1.10 76 6.91 135
Issuance of Debt
- - - - 7.50 15
Issuance of Common Equity
-0.06 131 0.00 37 0.00 71
Other Financing Activities, net
0.07 0.58 1.10 39 -0.59 49
Effect of Exchange Rate Changes
- - - - 0.09 0.60
Cash Income Taxes Paid
- - - - 0.22 0.02

Quarterly Cash Flow Statements for ImageneBio

This table details how cash moves in and out of ImageneBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-67 -8.58 69 -5.80 -7.20 22 72 -8.63 -18 19 -9.82
Net Cash From Operating Activities
-18 -13 13 -6.26 -7.23 -3.42 -27 -7.22 -15 -9.07 -9.52
Net Cash From Continuing Operating Activities
-18 -13 13 -6.26 -7.23 -3.42 -27 -7.22 -15 -9.07 -9.52
Net Income / (Loss) Continuing Operations
-16 -14 -1.88 -9.12 -6.08 -2.77 -27 -6.91 -11 -10 -16
Consolidated Net Income / (Loss)
-16 -14 -1.88 -9.12 -6.08 -2.77 -27 -6.91 -11 -10 -16
Amortization Expense
-0.39 -0.42 1.13 -0.29 0.08 -0.05 0.68 0.13 0.17 0.17 0.17
Non-Cash Adjustments To Reconcile Net Income
3.29 1.74 10 1.52 0.18 1.00 13 0.05 0.88 0.91 1.67
Changes in Operating Assets and Liabilities, net
-5.27 -0.18 2.68 1.54 -1.41 -1.69 -13 -0.88 -5.22 0.02 4.26
Net Cash From Investing Activities
-49 3.92 56 0.46 0.00 25 -37 -1.36 -0.44 -0.35 -0.39
Net Cash From Continuing Investing Activities
-49 3.92 56 0.46 0.00 25 -37 -1.36 -0.44 -0.35 -0.39
Purchase of Investments
-62 -9.97 72 -7.26 0.00 -6.00 22 -8.91 -11 -8.00 -5.67
Sale and/or Maturity of Investments
14 14 -17 15 0.00 46 -69 7.55 10 7.65 5.29
Net Cash From Financing Activities
0.00 - - - 0.03 - 135 - -3.24 28 0.08
Net Cash From Continuing Financing Activities
0.00 - - - 0.03 - 135 - -3.24 28 0.08
Repurchase of Common Equity
0.00 - - - -0.02 - - - 0.00 - -0.06
Issuance of Common Equity
0.00 - - - - - 71 - - - 0.03
Other Financing Activities, net
0.00 - - - 0.05 - 49 - -3.24 - 0.11

Annual Balance Sheets for ImageneBio

This table presents ImageneBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
168 248 172 192 16 153
Total Current Assets
166 237 160 179 12 140
Cash & Equivalents
162 232 60 120 12 95
Short-Term Investments
- 0.00 97 56 0.00 41
Prepaid Expenses
3.48 4.30 3.06 3.20 0.35 4.94
Plant, Property, & Equipment, net
1.39 2.44 3.21 2.34 0.00 0.00
Total Noncurrent Assets
0.17 8.92 9.04 11 3.45 13
Noncurrent Note & Lease Receivables
- - - - 0.00 7.02
Other Noncurrent Operating Assets
0.17 8.92 9.04 11 3.45 5.67
Total Liabilities & Shareholders' Equity
168 248 172 192 16 153
Total Liabilities
63 40 25 22 17 20
Total Current Liabilities
28 27 22 14 17 11
Accounts Payable
2.12 2.38 2.09 2.07 5.29 1.44
Accrued Expenses
5.40 5.85 8.34 8.58 3.46 7.53
Other Current Liabilities
0.19 1.85 1.91 3.56 0.31 2.26
Total Noncurrent Liabilities
35 13 3.79 8.13 0.24 8.60
Other Noncurrent Operating Liabilities
0.00 5.14 3.79 7.18 0.24 8.60
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-101 208 147 170 -161 133
Total Preferred & Common Equity
-101 208 147 170 -161 133
Preferred Stock
0.00 0.00 0.00 0.00 19 0.00
Total Common Equity
-101 208 147 170 -180 133
Common Stock
10 353 362 452 2.16 363
Retained Earnings
-111 -145 -214 -282 -180 -230
Accumulated Other Comprehensive Income / (Loss)
- 0.00 -0.76 -0.05 -1.79 0.09

Quarterly Balance Sheets for ImageneBio

This table presents ImageneBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
215 173 157 149 131 126 161 137 152 143
Total Current Assets
201 161 149 142 117 99 148 122 141 131
Cash & Equivalents
121 53 44 45 37 58 103 76 95 85
Short-Term Investments
76 104 101 93 77 37 39 41 41 42
Prepaid Expenses
3.70 3.82 3.90 3.50 2.95 3.37 4.95 4.80 4.96 4.00
Plant, Property, & Equipment, net
2.63 0.86 0.77 0.68 0.51 0.42 0.00 0.00 0.00 0.00
Total Noncurrent Assets
12 11 7.39 6.77 13 27 13 15 11 12
Noncurrent Note & Lease Receivables
- - - - - - 7.51 5.73 2.56 5.48
Other Noncurrent Operating Assets
12 11 7.39 6.77 13 27 5.84 8.95 8.37 6.46
Total Liabilities & Shareholders' Equity
215 173 157 149 131 126 161 137 152 143
Total Liabilities
28 17 15 15 13 10 21 13 9.97 14
Total Current Liabilities
19 10 8.20 9.24 8.79 7.32 11 6.63 6.57 8.08
Accounts Payable
3.95 1.91 1.41 1.54 0.81 0.51 2.08 0.57 0.98 0.93
Accrued Expenses
11 4.82 3.09 3.78 4.10 2.98 6.90 3.76 3.68 5.83
Other Current Liabilities
3.47 3.44 3.70 3.92 3.89 3.83 2.16 2.31 1.91 1.31
Total Noncurrent Liabilities
8.88 7.27 6.43 5.52 3.80 2.94 9.90 6.72 3.40 6.33
Other Noncurrent Operating Liabilities
8.02 7.27 6.43 5.52 3.80 2.94 9.90 6.72 3.40 6.33
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
155 155 143 134 118 116 140 123 142 128
Total Preferred & Common Equity
155 155 143 134 118 116 140 123 142 128
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
155 155 143 134 118 116 140 123 142 128
Common Stock
419 454 455 456 458 459 363 364 393 395
Retained Earnings
-263 -299 -312 -322 -340 -343 -223 -241 -251 -266
Accumulated Other Comprehensive Income / (Loss)
-0.29 -0.31 -0.35 0.24 0.10 0.07 0.09 -0.02 -0.05 -0.17

Annual Metrics And Ratios for ImageneBio

This table displays calculated financial ratios and metrics derived from ImageneBio's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 35,906,794.00 36,257,493.00 48,258,111.00 - 11,181,672.00
DEI Adjusted Shares Outstanding
0.00 2,992,233.00 3,021,458.00 4,021,509.00 - 11,181,672.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -11.40 -22.76 -16.95 - -4.69
Growth Metrics
- - - - - -
Revenue Growth
0.00% 237.01% -49.60% -41.35% -100.00% -77.14%
EBITDA Growth
0.00% 23.63% -108.85% -9.03% 24.87% -32.11%
EBIT Growth
0.00% 22.91% -107.87% -6.38% 25.16% -29.26%
NOPAT Growth
0.00% 23.32% -107.70% -6.36% 21.80% -30.95%
Net Income Growth
0.00% 22.91% -101.57% 0.87% 27.77% -24.01%
EPS Growth
0.00% 92.38% -55.74% 14.21% 37.42% 85.46%
Operating Cash Flow Growth
0.00% -59.29% -23.00% -7.60% 42.31% -124.42%
Free Cash Flow Firm Growth
0.00% 0.00% -10.36% 9.35% 16.14% -54.40%
Invested Capital Growth
0.00% 58.34% 59.01% 52.32% 154.83% 64.03%
Revenue Q/Q Growth
0.00% 186.00% -48.60% -34.35% -100.00% 122.86%
EBITDA Q/Q Growth
0.00% 46.30% -34.23% -10.12% 16.19% 22.29%
EBIT Q/Q Growth
0.00% 45.83% -33.70% -10.00% 16.66% 18.00%
NOPAT Q/Q Growth
0.00% 45.80% -33.79% -9.90% 13.74% 29.81%
Net Income Q/Q Growth
0.00% 45.82% -32.57% -8.59% 17.39% 13.36%
EPS Q/Q Growth
0.00% 90.18% -458.49% -1.24% 16.39% -63.67%
Operating Cash Flow Q/Q Growth
0.00% -1.34% -6.14% -5.51% 25.27% 30.45%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.26% -6.02% 8.12% 23.33%
Invested Capital Q/Q Growth
0.00% 42.91% 35.93% 46.49% 168.64% 19.67%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin
-478.09% -108.35% -448.92% -834.52% 0.00% -5,846.50%
Operating Margin
-484.22% -110.18% -453.99% -823.33% 0.00% -6,056.38%
EBIT Margin
-481.36% -110.10% -454.05% -823.57% 0.00% -5,966.75%
Profit (Net Income) Margin
-481.36% -110.10% -440.29% -744.17% 0.00% -5,668.63%
Tax Burden Percent
100.00% 100.07% 100.00% 99.76% 100.31% 99.23%
Interest Burden Percent
100.00% 99.93% 96.97% 90.57% 86.94% 95.74%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-42.18% -21.81% -38.76% -43.04% -33.30% -68.91%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -1,864.63% 0.00%
Operating Return on Assets (OROA)
-26.28% -16.39% -33.76% -41.41% 0.00% -56.52%
Return on Assets (ROA)
-26.28% -16.39% -32.73% -37.42% 0.00% -53.70%
Return on Common Equity (ROCE)
40.62% -7.45% -38.76% -43.04% -33.30% 24.29%
Return on Equity Simple (ROE_SIMPLE)
43.80% -16.41% -46.79% -40.16% -39.10% 0.00%
Net Operating Profit after Tax (NOPAT)
-31 -24 -50 -53 -41 -34
NOPAT Margin
-338.95% -77.12% -317.79% -576.33% 0.00% -4,239.46%
Net Nonoperating Expense Percent (NNEP)
-8.01% -5.17% -9.83% -9.28% -5.34% -16.34%
Return On Investment Capital (ROIC_SIMPLE)
- - - -30.93% -32.51% -25.47%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
96.43% 58.14% 142.15% 272.11% 0.00% 2,590.75%
R&D to Revenue
487.79% 152.03% 411.84% 651.22% 0.00% 3,565.63%
Operating Expenses to Revenue
584.22% 210.18% 553.99% 923.33% 0.00% 6,156.38%
Earnings before Interest and Taxes (EBIT)
-44 -34 -71 -75 -56 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-44 -34 -70 -76 -57 -47
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 2.17 0.66 0.56 0.63 0.58
Price to Tangible Book Value (P/TBV)
0.00 2.17 0.66 0.56 0.63 0.58
Price to Revenue (P/Rev)
13.60 14.53 6.18 10.38 0.00 96.44
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
18.33 7.04 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.00 0.00 0.01 0.01 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.01 0.01 0.00
Financial Leverage
-1.56 -1.26 -1.10 -1.05 -1.01 -1.06
Leverage Ratio
1.60 1.33 1.18 1.15 1.13 1.28
Compound Leverage Factor
1.60 1.33 1.15 1.04 0.98 1.23
Debt to Total Capital
0.00% 0.00% 0.00% 0.56% 0.84% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.56% 0.84% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
196.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-96.30% 100.00% 100.00% 99.44% 99.16% 100.00%
Debt to EBITDA
0.00 0.00 0.00 -0.01 -0.02 0.00
Net Debt to EBITDA
0.00 0.00 0.00 2.28 2.15 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 -0.01 -0.02 0.00
Debt to NOPAT
0.00 0.00 0.00 -0.02 -0.03 0.00
Net Debt to NOPAT
0.00 0.00 0.00 3.31 2.99 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 -0.02 -0.03 0.00
Altman Z-Score
0.42 6.62 0.24 0.27 -0.56 0.22
Noncontrolling Interest Sharing Ratio
196.30% 65.85% 0.00% 0.00% 0.00% 135.25%
Liquidity Ratios
- - - - - -
Current Ratio
5.86 8.70 7.44 12.58 11.80 12.49
Quick Ratio
5.74 8.54 7.30 12.35 11.54 12.05
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -58 -64 -58 -49 -38
Operating Cash Flow to CapEx
-4,938.12% -3,423.41% -5,178.83% -19,261.59% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.05 0.15 0.07 0.05 0.00 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
6.60 16.17 5.53 3.31 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-58 -24 -9.98 -4.76 2.61 -2.21
Invested Capital Turnover
-0.16 -0.75 -0.91 -1.24 0.00 -0.19
Increase / (Decrease) in Invested Capital
0.00 34 14 5.22 7.37 3.93
Enterprise Value (EV)
168 218 -61 -79 -44 -58
Market Capitalization
125 450 96 95 79 77
Book Value per Share
($36.54) $5.79 $4.05 $3.52 $2.61 $11.91
Tangible Book Value per Share
($36.54) $5.79 $4.05 $3.52 $2.61 $11.91
Total Capital
105 208 147 171 127 133
Total Debt
0.00 0.00 0.00 0.95 1.06 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.95 1.06 0.00
Net Debt
-162 -232 -157 -175 -123 -135
Capital Expenditures (CapEx)
0.77 1.76 1.43 0.41 -0.44 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-25 -23 -18 -11 -8.00 -6.30
Debt-free Net Working Capital (DFNWC)
138 209 139 164 116 129
Net Working Capital (NWC)
138 209 139 164 116 129
Net Nonoperating Expense (NNE)
13 10 19 15 7.95 11
Net Nonoperating Obligations (NNO)
-163 -232 -157 -175 -123 -135
Total Depreciation and Amortization (D&A)
0.30 0.54 0.80 -1.00 -0.98 0.96
Debt-free, Cash-free Net Working Capital to Revenue
-270.33% -73.87% -118.07% -120.17% 0.00% -786.88%
Debt-free Net Working Capital to Revenue
1,497.03% 675.58% 886.84% 1,795.38% 0.00% 16,131.75%
Net Working Capital to Revenue
1,497.03% 675.58% 886.84% 1,795.38% 0.00% 16,131.75%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.22) ($1.90) ($1.63) ($1.02) ($9.64)
Adjusted Weighted Average Basic Shares Outstanding
0.00 36.11M 36.19M 41.74M 48.26M 4.87M
Adjusted Diluted Earnings per Share
$0.00 ($1.22) ($1.90) ($1.63) ($1.02) ($9.64)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 36.11M 36.19M 41.74M 48.26M 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 ($1.22) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 27.98M 36.26M 48.26M 48.26M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-31 -24 -50 -53 -38 -34
Normalized NOPAT Margin
-338.95% -77.12% -317.79% -576.33% 0.00% -4,239.46%
Pre Tax Income Margin
-481.36% -110.03% -440.29% -745.94% 0.00% -5,712.38%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -0.97% 0.00% 0.00%

Quarterly Metrics And Ratios for ImageneBio

This table displays calculated financial ratios and metrics derived from ImageneBio's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
48,258,111.00 48,258,111.00 48,258,111.00 - 48,258,111.00 48,258,111.00 48,258,111.00 11,181,672.00 11,181,672.00 11,279,130.00 11,351,456.00
DEI Adjusted Shares Outstanding
4,021,509.00 4,021,509.00 4,021,509.00 - 4,021,509.00 4,021,509.00 4,021,509.00 11,181,672.00 11,181,672.00 11,279,130.00 11,351,456.00
DEI Earnings Per Adjusted Shares Outstanding
-4.01 -3.41 -1.54 - -2.27 -0.69 -6.37 -1.38 -0.95 -0.90 -1.38
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-100.00% -100.00% 195.36% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Growth
-16.40% 15.57% 93.49% 50.60% 67.84% 74.86% -1,778.31% -4,008.37% -95.46% -54.64% 35.18%
EBIT Growth
-17.52% 15.72% 83.45% 51.47% 67.09% 74.07% -666.71% -7,476.86% -95.63% -55.26% 35.20%
NOPAT Growth
-17.47% 14.42% 89.56% 42.87% 67.11% 44.70% -1,206.19% -152.79% -101.48% -60.15% 33.91%
Net Income Growth
-13.55% 19.78% 81.65% 53.18% 62.36% 79.85% -678.48% -161.73% -74.74% -34.19% 36.96%
EPS Growth
15.38% 36.36% 81.65% 50.00% 62.36% 78.57% -12.79% 13.19% 75.00% 85.87% 68.73%
Operating Cash Flow Growth
7.48% 31.09% 164.82% 71.31% 60.50% 72.63% -305.54% -107.71% -104.70% 23.76% 55.71%
Free Cash Flow Firm Growth
50.72% 70.34% 67.95% 21.54% 23.25% -217.15% -201.80% -844.88% 0.21% 121.79% 15.35%
Invested Capital Growth
28.27% -318.30% 57.25% 154.83% 309.74% 891.60% 27.62% 64.03% 45.73% -70.78% 156.02%
Revenue Q/Q Growth
-100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth
16.07% 13.51% 91.89% 11.70% -2,853.49% 60.45% -505.92% 65.35% -37.70% 2.88% -47.85%
EBIT Q/Q Growth
16.83% 14.51% 79.29% 11.30% -5,058.68% 59.62% -512.49% 63.95% -31.50% 2.79% -47.14%
NOPAT Q/Q Growth
16.81% 13.18% 87.13% -0.89% -555.19% 18.94% -203.93% 91.30% -422.22% 2.44% -46.89%
Net Income Q/Q Growth
17.15% 14.96% 76.82% 10.85% -73.18% 67.90% -795.52% 62.94% -15.63% 4.15% -53.47%
EPS Q/Q Growth
17.50% 15.15% 76.82% 4.76% -73.18% 66.67% -4,750.00% -8.59% 69.94% 33.68% -44.44%
Operating Cash Flow Q/Q Growth
16.11% 31.70% 203.68% 29.96% -108.06% 67.60% -678.55% 72.91% -105.04% 38.70% -4.94%
Free Cash Flow Firm Q/Q Growth
34.10% 32.62% 28.61% -17.08% -1,494.70% -110.44% 32.07% 71.76% -86.84% 158.75% -369.20%
Invested Capital Q/Q Growth
57.92% -27.87% -48.48% 168.64% 168.34% 382.61% -113.58% 19.67% 376.88% -3.24% -73.97%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 100.00% 0.00% 100.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% -36.89% 0.00% -740.00% 0.00% 0.00% -1,050.38% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% -58.17% 0.00% -749.38% 0.00% 0.00% -289.13% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% -92.26% 0.00% -750.00% 0.00% 0.00% -1,115.75% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% -90.94% 0.00% -759.63% 0.00% 0.00% -1,148.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.17% 100.45% 100.00% 100.58% 100.00% 100.55% 99.70% 96.64% 100.09% 100.16% 100.13%
Interest Burden Percent
88.41% 87.68% 98.58% 85.26% 101.28% 68.09% 100.39% 106.46% 90.38% 89.06% 92.92%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -2,053.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -2,051.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 2,035.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-48.28% -44.54% -32.70% -33.30% -17.86% -23.76% -38.20% -68.91% -41.30% -40.69% -32.34%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -1,864.63% -560.59% -266.24% 0.00% 0.00% -777.18% -205.67% -2,553.32%
Operating Return on Assets (OROA)
0.00% 0.00% -2.11% 0.00% -21.24% 0.00% 0.00% -10.57% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% -2.08% 0.00% -21.52% 0.00% 0.00% -10.88% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-48.28% -44.54% -29.46% -33.30% -17.86% -23.76% -38.20% 24.29% -41.30% -40.69% -32.34%
Return on Equity Simple (ROE_SIMPLE)
-45.12% -46.70% 0.00% 0.00% 0.00% -26.52% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -11 -1.43 -8.76 -4.20 -6.13 -19 -1.62 -8.46 -8.25 -12
NOPAT Margin
0.00% 0.00% -40.72% 0.00% -524.56% 0.00% 0.00% -202.39% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.30% -1.75% -1.05% -0.24% -1.39% 2.79% -4.39% -10.81% -1.87% -1.66% -2.60%
Return On Investment Capital (ROIC_SIMPLE)
-8.21% -7.75% -1.06% -6.90% -3.55% -5.28% -13.31% -1.22% -6.86% -5.81% -9.46%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 47.17% 0.00% 344.38% 0.00% 0.00% -46.25% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 111.00% 0.00% 505.00% 0.00% 0.00% 653.38% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 158.17% 0.00% 849.38% 0.00% 0.00% 389.13% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-18 -16 -3.23 -11 -6.00 -4.04 -25 -8.93 -12 -11 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -16 -1.29 -11 -5.92 -4.00 -24 -8.40 -12 -11 -17
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.44 0.56 0.62 0.63 0.52 0.56 0.23 0.58 0.45 0.47 0.41
Price to Tangible Book Value (P/TBV)
0.44 0.56 0.62 0.63 0.52 0.56 0.23 0.58 0.45 0.47 0.41
Price to Revenue (P/Rev)
17.81 43.20 20.08 0.00 14.37 0.00 0.00 96.44 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.02 -1.01 -1.04 -1.01 -0.99 -0.93 -1.02 -1.06 -0.96 -0.90 -1.00
Leverage Ratio
1.12 1.10 1.13 1.13 1.11 1.10 1.13 1.28 1.11 1.08 1.13
Compound Leverage Factor
0.99 0.96 1.12 0.96 1.12 0.75 1.14 1.37 1.00 0.96 1.05
Debt to Total Capital
0.00% 0.00% 0.00% 0.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 99.16% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 2.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 2.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.66 1.25 1.39 0.51 0.18 0.74 -0.52 1.05 0.78 2.51 0.19
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 9.91% 0.00% 0.00% 0.00% 0.00% 135.25% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
15.85 18.22 15.32 11.80 13.31 13.52 13.24 12.49 18.39 21.47 16.17
Quick Ratio
15.47 17.74 14.94 11.54 12.97 13.06 12.79 12.05 17.67 20.71 15.68
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-14 -9.13 -6.52 -16 -10 -29 -20 -5.55 -10 6.10 -16
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.02 0.01 0.02 0.00 0.03 0.00 0.00 0.01 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.93 1.01 2.51 0.00 6.28 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.00 -2.56 -3.80 2.61 4.20 20 -2.75 -2.21 6.12 5.92 1.54
Invested Capital Turnover
-1.61 -1.16 -0.66 0.00 3.91 0.00 0.00 -0.19 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.79 -1.95 5.09 7.37 6.20 23 1.05 3.93 1.92 -14 4.29
Enterprise Value (EV)
-89 -66 -55 -44 -52 -31 -110 -58 -61 -70 -75
Market Capitalization
69 80 83 79 62 65 33 77 56 67 52
Book Value per Share
$3.22 $2.96 $2.78 $2.61 $2.45 $2.40 $2.90 $11.91 $5.50 $12.60 $11.29
Tangible Book Value per Share
$3.22 $2.96 $2.78 $2.61 $2.45 $2.40 $2.90 $11.91 $5.50 $12.60 $11.29
Total Capital
155 143 134 127 118 116 140 133 123 142 128
Total Debt
0.00 0.00 0.00 1.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 1.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-157 -145 -138 -123 -114 -96 -143 -135 -117 -136 -127
Capital Expenditures (CapEx)
-0.06 -0.19 -0.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-6.35 -4.29 -5.74 -8.00 -5.85 -3.95 -6.20 -6.30 -1.84 -1.61 -4.08
Debt-free Net Working Capital (DFNWC)
151 141 132 116 108 92 136 129 115 135 123
Net Working Capital (NWC)
151 141 132 116 108 92 136 129 115 135 123
Net Nonoperating Expense (NNE)
3.39 2.65 1.76 0.36 1.88 -3.36 6.16 7.56 2.16 1.93 3.50
Net Nonoperating Obligations (NNO)
-157 -145 -138 -123 -114 -96 -143 -135 -117 -136 -127
Total Depreciation and Amortization (D&A)
-0.17 -0.33 1.94 -0.20 0.08 0.04 0.51 0.52 0.17 0.17 0.17
Debt-free, Cash-free Net Working Capital to Revenue
-165.12% -232.99% -138.05% 0.00% -135.93% 0.00% 0.00% -786.88% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
3,925.06% 7,657.35% 3,181.65% 0.00% 2,516.42% 0.00% 0.00% 16,131.75% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
3,925.06% 7,657.35% 3,181.65% 0.00% 2,516.42% 0.00% 0.00% 16,131.75% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.33) ($0.28) ($2.52) ($0.20) ($2.16) ($0.06) ($2.91) ($3.16) ($0.95) ($0.63) ($0.91)
Adjusted Weighted Average Basic Shares Outstanding
48.26M 48.26M 4.02M 48.26M 4.02M 48.26M 8.53M 4.87M 22.42M 0.00 17.12M
Adjusted Diluted Earnings per Share
($0.33) ($0.28) ($2.52) ($0.20) ($2.16) ($0.06) ($2.91) ($3.16) ($0.95) ($0.63) ($0.91)
Adjusted Weighted Average Diluted Shares Outstanding
48.26M 48.26M 4.02M 48.26M 4.02M 48.26M 0.00 0.00 22.42M 16.16M 17.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.16) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
48.26M 48.26M 4.02M 48.26M 4.02M 48.26M 11.18M 0.00 11.28M 11.35M 12.46M
Normalized Net Operating Profit after Tax (NOPAT)
-11 -11 -1.43 -8.52 -4.20 -5.91 -19 -1.62 -8.46 -8.25 -12
Normalized NOPAT Margin
0.00% 0.00% -40.72% 0.00% -524.56% 0.00% 0.00% -202.39% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% -90.94% 0.00% -759.63% 0.00% 0.00% -1,187.88% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

IMA remains a pre-revenue biotechnology company with substantial liquidity but continued operating losses. The latest statements identify the issuer as Ikena Oncology, Inc. (the data also references the former ticker IKNA), so investors should verify the company and ticker information before relying on these figures.

  • Liquidity remains strong. As of June 30, 2026, cash and equivalents totaled $94.7 million, while short-term investments added $41.5 million. Combined liquid resources of approximately $136.2 million increased from $117.2 million at the end of the first quarter.
  • The balance sheet carries little traditional debt. Total liabilities were $10.0 million versus $142.1 million of equity. Current assets of $141.1 million compared with current liabilities of only $6.6 million, indicating substantial short-term balance-sheet flexibility.
  • Quarterly operating cash burn improved sequentially. Net cash used in operating activities declined to $9.1 million in Q2 2026 from $14.8 million in Q1 2026 and $26.6 million in Q3 2025. This suggests lower cash consumption despite the company remaining unprofitable.
  • Operating expenses have declined materially from 2025 levels. Q2 2026 selling, general and administrative expense was $5.1 million and research and development expense was $6.7 million, producing total operating expenses of $11.8 million. That compares with $26.6 million in Q3 2025 and $15.8 million in Q2 2024.
  • Interest and investment income is providing a meaningful offset to losses. Q2 2026 interest and investment income was $1.2 million, compared with a $577,000 loss in Q4 2025. The company’s sizable cash and investment portfolio continues to generate non-operating income.
  • Financing activity replenished cash in the latest quarter. Financing activities generated $28.0 million in Q2 2026, more than offsetting operating and investing cash outflows and resulting in an $18.6 million increase in cash and equivalents during the quarter.
  • Net losses have fluctuated but generally improved from the most severe 2025 quarters. Net loss was $10.2 million in Q2 2026, compared with $10.6 million in Q1 2026 and $27.8 million in Q3 2025. However, the company has not generated consistent profitability during the periods provided.
  • Cash management has relied heavily on investment transactions and capital markets. The company regularly purchases and sells short-term investments, while large financing inflows—such as the $135.5 million received in Q3 2025—have been important sources of liquidity. This pattern is typical for a development-stage biotechnology company but is not a substitute for recurring operating revenue.
  • Revenue remains absent in the latest period. IMA reported zero operating revenue in Q1 and Q2 2026, following $800,000 in Q4 2025 and no revenue in Q2 and Q3 2025. The business therefore remains dependent on cash reserves, investment income and financing rather than commercial operations.
  • The company continues to consume cash and accumulate losses. Q2 2026 retained earnings were negative $250.9 million, and operating cash flow has been negative in each of the recent quarters provided. At the Q2 operating burn rate, the company appears to have several years of liquidity before considering potential changes in spending, investment returns or additional financing, but that runway could shorten if research spending rises or capital markets become less favorable.
  • Recent financing may create dilution risk. Common stock increased from $364.0 million at March 31, 2026, to $393.0 million at June 30, 2026, while financing activities supplied $28.0 million. Earlier periods also included significant equity-related financing, including $135.5 million in Q3 2025, indicating that future capital raises could dilute existing shareholders.
  • Research and development spending remains substantial relative to revenue. The company spent $6.7 million on R&D in Q2 2026 despite reporting no revenue. Continued investment may be necessary to advance its pipeline, but it will continue pressuring earnings and cash flow until products or partnerships generate sustainable returns.

Overall, the financial statements show a company with a comparatively strong liquidity position and low liabilities, but no current revenue base and persistent dependence on external capital. The most important factors for investors are whether the company can convert its research programs into partnerships or commercial revenue, maintain its lower cash-burn rate, and fund operations without excessive shareholder dilution.

11/17/26 11:06 AM ETAI Generated. May Contain Errors.

ImageneBio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ImageneBio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ImageneBio had net income of -$45.35 million at the end of 2025, a 24.0% decrease from 2024, and a 2.5% decrease since 2020. See ImageneBio's forecast for analyst expectations on what's next for the company.

ImageneBio's total operating income in 2025 was -$48.45 million, based on the following breakdown:
  • Total Gross Profit: $800 thousand
  • Total Operating Expenses: $49.25 million

Over the last 5 years, ImageneBio's total revenue changed from $9.19 million in 2020 to $800 thousand in 2025, a change of -91.3%.

In the past 12 quarters, ImageneBio's cash and equivalents has ranged from $36.76 million in Q1 2025 to $121.28 million in Q3 2023, and is currently $84.85 million as of their latest financial filing in Q3 2026.

ImageneBio had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2020.

Over the last 5 years, ImageneBio's book value per share changed from -36.54 in 2020 to 11.91 in 2025.



Financial statements for NASDAQ:IMA last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners